CRL vs NVAX · rev $2.00B vs P/E 2.5, rev $196.2M
Charles River Laboratories (CRL) versus Novavax Inc (NVAX) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Novavax Inc (NVAX) is a biotechnology company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
CRL currently screens at market cap $7.78B. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Not investment advice. Open the CRL and NVAX stock pages for the full models.
Not investment advice.